Bank Of Montreal

ProShares Ultra Bloomberg Natural Gas

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

VS TR -1x Short VIX Futures ETF

Direxion Daily Semicondct Bull 3X ETF

Direxion Daily Small Cap Bull 3X ETF

ARK Innovation ETF

United States Natural Gas

Direxion Daily Gold Miners Bear 3X ETF

Direxion Daily Technology Bull 3X ETF

VS TR 2x Long VIX Futures ETF

ProShares Ultra VIX Short-Term Futures

ProShares UltraShort Bloomberg Natrl Gas

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily Small Cap Bear 3X ETF

Direxion Daily Semicondct Bear 3X ETF

Direxion Daily Gold Miners Bull 3X ETF

Direxion Technology Bear 3X Shares

ProShares Trust ProShares Short Bitcoin Strategy ETF

Archer Aviation Inc. Class A Common Stock

Leggett & Platt Incorporated Common Stock

Olin Corporation Common Stock

Oklo Inc.

Cameco Corporation Common Stock

XPeng Inc. American depositary shares each representing two Class A ordinary shares

ICL Group Ltd. Ordinary Shares

Northern Oil and Gas Inc. Common Stock

Alaska Air Group Inc. Common Stock

GameStop Corporation Common Stock

JELD-WEN Holding Inc. Common Stock

Granite Point Mortgage Trust Inc. Common Stock

AgEagle Aerial Systems Inc. Common Stock

Agnico Eagle Mines Limited Common Stock

Banc of California Inc. Common Stock

JinkoSolar Holding Company Limited American Depositary Shares (each representing 4 Common Shares)

New Gold Inc.

Mitsubishi UFJ Financial Group Inc. Common Stock

Pan American Silver Corp. Common Stock

Merck & Company Inc. Common Stock (new)

Click here to get full coverage on Insider Spends US$100k Buying More Shares In Aytu BioPharma - simplywall.st

Insider Spends US$100k Buying More Shares In Aytu BioPharma  simplywall.st

Insider Spends US$100k Buying More Shares In Aytu BioPharma - simplywall.st

Click here to get full coverage on Aytu BioPharma to commercialise Exxua for MDD in the US - Pharmaceutical Technology

Aytu BioPharma to commercialise Exxua for MDD in the US  Pharmaceutical Technology

Aytu BioPharma to commercialise Exxua for MDD in the US - Pharmaceutical Technology

Click here to get full coverage on Breakthrough: First Depression Drug Without Sexual Side Effects Gets $16.6M Backing for Q4 Launch - Stock Titan

Breakthrough: First Depression Drug Without Sexual Side Effects Gets $16.6M Backing for Q4 Launch  Stock Titan

Breakthrough: First Depression Drug Without Sexual Side Effects Gets $16.6M Backing for Q4 Launch - Stock Titan

Click here to get full coverage on Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com

Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock  Investing.com

Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com

Click here to get full coverage on Insider Buying Spree: Top Executives Invest Big in Aytu BioScience! - TipRanks

Insider Buying Spree: Top Executives Invest Big in Aytu BioScience!  TipRanks

Insider Buying Spree: Top Executives Invest Big in Aytu BioScience! - TipRanks

Click here to get full coverage on Transcript : Aytu BioPharma, Inc. - Special Call - marketscreener.com

Transcript : Aytu BioPharma, Inc. - Special Call  marketscreener.com

Transcript : Aytu BioPharma, Inc. - Special Call - marketscreener.com

Click here to get full coverage on Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharm - GuruFocus

Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharm  GuruFocus

Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharm - GuruFocus

Click here to get full coverage on AYTU BIOPHARMA Executives Increase Stake in Company - TradingView

AYTU BIOPHARMA Executives Increase Stake in Company  TradingView

AYTU BIOPHARMA Executives Increase Stake in Company - TradingView

Click here to get full coverage on Aytu BioPharma to commercialise Exxua antidepressant in US - World Pharmaceutical Frontiers

Aytu BioPharma to commercialise Exxua antidepressant in US  World Pharmaceutical Frontiers

Aytu BioPharma to commercialise Exxua antidepressant in US - World Pharmaceutical Frontiers

Click here to get full coverage on Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan - ACCESS Newswire

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan  ACCESS Newswire

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma Closes $16.6M Stock Offering for EXXUA - TipRanks

Aytu BioPharma Closes $16.6M Stock Offering for EXXUA  TipRanks

Aytu BioPharma Closes $16.6M Stock Offering for EXXUA - TipRanks

Click here to get full coverage on Aytu BioPharma Secures $14.4M Financing: Major Funds Back EXXUA Depression Drug Commercialization - Stock Titan

Aytu BioPharma Secures $14.4M Financing: Major Funds Back EXXUA Depression Drug Commercialization  Stock Titan

Aytu BioPharma Secures $14.4M Financing: Major Funds Back EXXUA Depression Drug Commercialization - Stock Titan

Click here to get full coverage on Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock - ACCESS Newswire

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock  ACCESS Newswire

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma Announces Closing of Upsized At the Market Public - GuruFocus

Aytu BioPharma Announces Closing of Upsized At the Market Public  GuruFocus

Aytu BioPharma Announces Closing of Upsized At the Market Public - GuruFocus

Click here to get full coverage on Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps - Investing.com

Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps  Investing.com

Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps - Investing.com

Click here to get full coverage on Aytu BioPharma’s Strategic Acquisition of EXXUA Drives Buy Rating and Raises Price Target - TipRanks

Aytu BioPharma’s Strategic Acquisition of EXXUA Drives Buy Rating and Raises Price Target  TipRanks

Aytu BioPharma’s Strategic Acquisition of EXXUA Drives Buy Rating and Raises Price Target - TipRanks

Click here to get full coverage on New Antidepressant EXXUA Enters $22B Market Without Sexual Side Effects | AYTU Stock News - Stock Titan

New Antidepressant EXXUA Enters $22B Market Without Sexual Side Effects | AYTU Stock News  Stock Titan

New Antidepressant EXXUA Enters $22B Market Without Sexual Side Effects | AYTU Stock News - Stock Titan

Click here to get full coverage on Aytu BioPharma Announces $12.9M Public Offering - TipRanks

Aytu BioPharma Announces $12.9M Public Offering  TipRanks

Aytu BioPharma Announces $12.9M Public Offering - TipRanks

Click here to get full coverage on AYTU - Aytu Biopharma Inc Latest Stock News & Market Updates - Stock Titan

AYTU - Aytu Biopharma Inc Latest Stock News & Market Updates  Stock Titan

AYTU - Aytu Biopharma Inc Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Aytu BioScience Signs Exclusive Agreement for EXXUA - TipRanks

Aytu BioScience Signs Exclusive Agreement for EXXUA  TipRanks

Aytu BioScience Signs Exclusive Agreement for EXXUA - TipRanks

Click here to get full coverage on Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in the United Kingdom - ACCESS Newswire

Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in the United Kingdom  ACCESS Newswire

Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in the United Kingdom - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma prices 9.6M shares at $1.50 in upsized public offering - TipRanks

Aytu BioPharma prices 9.6M shares at $1.50 in upsized public offering  TipRanks

Aytu BioPharma prices 9.6M shares at $1.50 in upsized public offering - TipRanks

Click here to get full coverage on Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com Australia

Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock  Investing.com Australia

Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com Australia

Click here to get full coverage on Aytu BioPharma Reports Strong Q3 2025 Earnings - TipRanks

Aytu BioPharma Reports Strong Q3 2025 Earnings  TipRanks

Aytu BioPharma Reports Strong Q3 2025 Earnings - TipRanks

Click here to get full coverage on We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation - simplywall.st

We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation  simplywall.st

We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation - simplywall.st

Click here to get full coverage on Aytu BioScience Holds 2025 Annual Meeting - TipRanks

Aytu BioScience Holds 2025 Annual Meeting  TipRanks

Aytu BioScience Holds 2025 Annual Meeting - TipRanks

Click here to get full coverage on Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market  ACCESS Newswire

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma, Inc. (NASDAQ:AYTU) On The Verge Of Breaking Even - simplywall.st

Aytu BioPharma, Inc. (NASDAQ:AYTU) On The Verge Of Breaking Even  simplywall.st

Aytu BioPharma, Inc. (NASDAQ:AYTU) On The Verge Of Breaking Even - simplywall.st

Click here to get full coverage on Aytu Biopharma chief business officer buys $24,999 in stock By Investing.com - Investing.com South Africa

Aytu Biopharma chief business officer buys $24,999 in stock By Investing.com  Investing.com South Africa

Aytu Biopharma chief business officer buys $24,999 in stock By Investing.com - Investing.com South Africa

Click here to get full coverage on Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27%  simplywall.st

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st

Click here to get full coverage on Aytu BioScience Reports Strong Earnings and Strategic Success - TipRanks

Aytu BioScience Reports Strong Earnings and Strategic Success  TipRanks

Aytu BioScience Reports Strong Earnings and Strategic Success - TipRanks

Click here to get full coverage on Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of Exxua Tablets | AYTU Stock News - GuruFocus

Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of Exxua Tablets | AYTU Stock News  GuruFocus

Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of Exxua Tablets | AYTU Stock News - GuruFocus

Click here to get full coverage on Aytu BioPharma (AYTU) Announces Upsized Public Offering to Fund - GuruFocus

Aytu BioPharma (AYTU) Announces Upsized Public Offering to Fund  GuruFocus

Aytu BioPharma (AYTU) Announces Upsized Public Offering to Fund - GuruFocus

Click here to get full coverage on Aytu BioPharma Reports Fiscal 2025 Third Quarter Results - TradingView

Aytu BioPharma Reports Fiscal 2025 Third Quarter Results  TradingView

Aytu BioPharma Reports Fiscal 2025 Third Quarter Results - TradingView

Click here to get full coverage on Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - ACCESS Newswire

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results  ACCESS Newswire

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock | AYTU Stock News - GuruFocus

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock | AYTU Stock News  GuruFocus

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock | AYTU Stock News - GuruFocus

Click here to get full coverage on Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News - GuruFocus

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News  GuruFocus

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News - GuruFocus

Click here to get full coverage on AYTU Increases Common Stock Offering to 9.6 Million Shares | AYT - GuruFocus

AYTU Increases Common Stock Offering to 9.6 Million Shares | AYT  GuruFocus

AYTU Increases Common Stock Offering to 9.6 Million Shares | AYT - GuruFocus

Click here to get full coverage on AytuBioPharma (AYTU) Secures Exclusive Rights to Commercialize EXXUA in the U.S. | AYTU Stock News - GuruFocus

AytuBioPharma (AYTU) Secures Exclusive Rights to Commercialize EXXUA in the U.S. | AYTU Stock News  GuruFocus

AytuBioPharma (AYTU) Secures Exclusive Rights to Commercialize EXXUA in the U.S. | AYTU Stock News - GuruFocus

Click here to get full coverage on Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary  TradingView

Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Click here to get full coverage on Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini

Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd  Wilson Sonsini

Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini

Click here to get full coverage on AYTU: Lake Street Takes Role as Sole Book-Running Manager | AYTU Stock News - GuruFocus

AYTU: Lake Street Takes Role as Sole Book-Running Manager | AYTU Stock News  GuruFocus

AYTU: Lake Street Takes Role as Sole Book-Running Manager | AYTU Stock News - GuruFocus

Click here to get full coverage on Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance

Aytu BioPharma Proposes Settlement in Shareholder Lawsuit  Yahoo Finance

Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance

Click here to get full coverage on Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2 - GuruFocus

Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2  GuruFocus

Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2 - GuruFocus

Click here to get full coverage on Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats Estimates, Revenue Surges to $18.5 Million, Exceeding Expectations - GuruFocus

Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats Estimates, Revenue Surges to $18.5 Million, Exceeding Expectations  GuruFocus

Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats Estimates, Revenue Surges to $18.5 Million, Exceeding Expectations - GuruFocus

Click here to get full coverage on Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals - ACCESS Newswire

Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals  ACCESS Newswire

Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer P - GuruFocus

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer P  GuruFocus

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer P - GuruFocus

Click here to get full coverage on Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 - ACCESS Newswire

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025  ACCESS Newswire

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat - GuruFocus

Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat  GuruFocus

Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat - GuruFocus

Click here to get full coverage on Aytu BioPharma secures exclusive rights to new MDD drug By Investing.com - Investing.com India

Aytu BioPharma secures exclusive rights to new MDD drug By Investing.com  Investing.com India

Aytu BioPharma secures exclusive rights to new MDD drug By Investing.com - Investing.com India

Click here to get full coverage on Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations - ACCESS Newswire

Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations  ACCESS Newswire

Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations - ACCESS Newswire

Click here to get full coverage on Watchlist #3 - by Sergio Heiber - Microcap Opportunities - substack.com

Watchlist #3 - by Sergio Heiber - Microcap Opportunities  substack.com

Watchlist #3 - by Sergio Heiber - Microcap Opportunities - substack.com

Click here to get full coverage on Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms - ACCESS Newswire

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms  ACCESS Newswire

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms - ACCESS Newswire

Click here to get full coverage on Aytu BioPharma Announces Indefinite Suspension of AR101 Clinical Development Program for vEDS - The Ehlers Danlos Society

Aytu BioPharma Announces Indefinite Suspension of AR101 Clinical Development Program for vEDS  The Ehlers Danlos Society

Aytu BioScience Inc (AYTU)

Price Chart

Key Statistics

Technicals

About AYTU

Latest News

Insider Spends US$100k Buying More Shares In Aytu BioPharma - simplywall.st

Aytu BioPharma to commercialise Exxua for MDD in the US - Pharmaceutical Technology

Breakthrough: First Depression Drug Without Sexual Side Effects Gets $16.6M Backing for Q4 Launch - Stock Titan

Advanced Charts

Top Gainers

Top Losers